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Pegionalization of ST-Segment
levation Acute Coronary Syndromes Care
utting a National Policy in Proper Perspective
aif S. Rathore, MPH,* Andrew J. Epstein, PHD, MPP,† Brahmajee K. Nallamothu, MD, MPH,
arlan M. Krumholz, MD, SM*†‡§
ew Haven, Connecticut; and Ann Arbor, Michigan
A uniform policy for regionalization of ST-segment elevation myocardial infarction
(STEMI) care raises several concerns. Transferring all STEMI patients to obtain primary
percutaneous coronary intervention (PCI) may be less effective than transferring only
high-risk STEMI patients. Delays in time to treatment60 min associated with transferring
patients for primary PCI may result in increased mortality for the average patient as compared
with providing immediate fibrinolytic therapy at their initial hospital; yet more than 95% of
patients transferred for primary PCI in the U.S. exceed this 60-min benchmark. Superior
outcomes associated with treatment at higher-volume regional STEMI centers are inconsis-
tent among centers, and there is no direct evidence that patients will benefit by a transfer to
a high-volume hospital from a low-volume hospital. Published data suggest as many as 800
PCI patients would need to be transferred to a high-volume PCI hospital to avoid a single
death at a low-volume PCI hospital. Although European randomized trial data suggest
transferring patients with STEMI for primary PCI may be superior to immediate fibrinolytic
therapy, these findings are unlikely to generalize to the U.S. health care system given size,
geography, and organization. ST segment elevation myocardial infarction care regionalization
would require a massive redistribution of health care resources, depriving several hospitals of
advanced cardiac care facilities, expertise, and associated revenue. Clearer evidence of the
benefits and discussion of potential harms are needed before adopting a national STEMI
regionalization policy. (J Am Coll Cardiol 2006;47:1346–9) © 2006 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.053College of Cardiology Foundation
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rHowever beautiful the strategy, you should occasionally look at
the results.
—Winston Churchill (1)
he quality of care provided to patients hospitalized with
T-segment elevation myocardial infarction (STEMI) in
he U.S. leaves room for improvement. Recent studies
rovide evidence of shortfalls in the overall use of guideline-
ecommended treatment and inappropriate variations in
reatment, including by race, gender, geographic location,
nd time and day of presentation (2–5). Although efforts
uch as the American College of Cardiology’s Guidelines
pplied in Practice program have focused on improving the
uality of care provided at all hospitals currently treating
atients with STEMI, some have suggested that notable
mprovements require an extensive reconfiguration in the
ay we provide care for acute coronary syndromes (ACS) in
he U.S. (6,7).
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005, accepted November 8, 2005.Henry et al. (8) offer the most recent version of this
pproach. Their proposal advocates a national policy mod-
led on trauma care whereby patients with STEMI would
e routed directly to designated STEMI centers, potentially
ypassing closer centers. Improving the treatment of
TEMI is a laudable goal. Nevertheless, we remain troubled
y the lack of robust data supporting such a sweeping
hange in clinical practice and the continued lack of
ttention paid to the practical implications of this approach
9). In this paper, we explain why the claimed benefits of
TEMI regionalization may not be realized and present
otential unintended harms that may be associated with
uch a policy.
laim 1: primary percutaneous coronary intervention (PCI)
s superior to fibrinolytic therapy for all patients. Although
rimary PCI may yield better clinical outcomes than fi-
rinolytic therapy when delivered promptly and at experi-
nced centers (10), a large number of patients may not
ccrue this benefit. A study of 10 trials of reperfusion
herapy indicated that focusing the use of primary PCI on
hose approximately 40% of patients at highest risk would
chieve similar outcomes to treating all patients with pri-
ary PCI (11). More recent data suggest that the incre-
ental benefit of primary PCI is modified by patient risk,
ith no benefit for primary PCI as compared with fibrino-
ytic therapy in the large number of patients who are at low
isk (12). As such, a primary PCI-only strategy may have
egative consequences for lower-risk patients. These pa-
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April 4, 2006:1346–9 Treatment of ST-Segment Elevation ACSients are unlikely to achieve a substantive improvement in
utcomes with primary PCI compared with fibrinolysis, yet
ay incur an increased risk because of the delay required for
ransfer to primary PCI-capable centers. Further, patients
reated within the first 2 to 3 h of symptom onset may
chieve comparable outcomes with fibrinolytic therapy as
ith primary PCI, on average (13,14). Given the continued
volution of adjuvant and fibrinolytic therapies (15) and
nitial results with pre-hospital fibrinolytic treatment, there
ill be a continued need to assess the utility of different
brinolytic treatment regimens compared with primary
CI. In the interim, a more pragmatic approach would
ocus on treating with primary PCI those STEMI patients
ho are most likely to benefit or are ineligible for fibrino-
ytic therapy, rather than implementing a “one size fits all”
olicy.
Transferring patients to regional STEMI centers or
ypassing closer hospitals capable of providing fibrinolytic
herapy will increase time to treatment. Even among pa-
ients undergoing primary PCI, delays to reperfusion are
ssociated with an increased risk of in-hospital and long-
erm mortality (16). Although published studies of transfer
ndicate that the absolute rate of ventricular arrhythmia or
eath is 2% during transfer, this estimate may not be
eneralizable given the small numbers and selected nature of
andomized controlled trial populations. In the real world, it
ill likely be higher due to longer transfer times and sicker
atient populations.
Even more concerning is the absence of discussion
egarding how much additional delay in treatment is accept-
ble to obtain primary PCI in patients who are eligible for
mmediate fibrinolytic therapy. Work by Nallamothu and
ates (17) suggests that the incremental benefit of primary
CI over fibrinolytic therapy noted in randomized con-
rolled trials may be negated when delays for primary PCI
xceed the time it would take to deliver fibrinolytic therapy
y 60 min. Thus, in order for admissions to regional
TEMI centers in lieu of nearest available facilities to be
ffective, the total time from the door of the first hospital to
nitial balloon inflation during PCI at the second hospital
hould not be more than 90 min—or 60 min longer than
he 30 min typically required to deliver fibrinolytic therapy
t the first hospital. Data from the National Registry of
yocardial Infarction-2 and -3, however, report that pa-
ients undergoing interhospital transfer for PCI in the U.S.
xperience a median time from presentation at the first
ospital to PCI at the second hospital of 180 min (18). In
Abbreviations and Acronyms
ACS  acute coronary syndromes
EMS  emergency medical services
PCI  percutaneous coronary intervention
STEMI  ST-segment elevation myocardial infarctionact, fewer than 5% of interhospital transfers in the U.S. sccur within 90 min (18). Thus, for patients who have no
ontraindications to fibrinolysis and would incur a substan-
ial treatment-associated delay, prompt fibrinolysis at the
losest available hospital will do as much or more to
aximize outcomes than would transfer to a regional ACS
enter.
laim 2: directing patients to ACS centers with higher
olume, more specialists, and more intensive treatment
ill improve their outcomes. There are limited data re-
arding the association between hospital STEMI volume
nd outcomes. Proponents of STEMI regionalization have
elied instead on studies of hospital PCI volume and
utcomes to suggest that restricting STEMI patients to
igher-volume PCI centers will improve outcomes. Al-
hough higher-volume PCI centers have superior outcomes
ompared with lower-volume PCI centers (19), recent
tudies suggest hospital PCI volume is a poor marker for
ndividual hospital PCI outcomes (20). Hospital PCI
olume-associated differences in mortality have decreased in
he past 20 years, and overall differences in mortality
etween high- and low-volume PCI centers are negligible
21). We are not aware of any studies that experimentally
valuate whether shifting patients from low-volume PCI
enters to high-volume PCI centers improves outcomes. A
tudy using administrative data assessed the national impact
f transferring all PCI procedures from hospitals perform-
ng fewer than 200 PCI cases annually to hospitals with
ore than 200 annual PCI cases. In a best-case scenario, in
hich transferred patients obtain the superior outcomes of
he receiving hospital, more than 800 patients would have to
e transferred from low-volume PCI hospitals to avoid a
ingle death (22). Regardless, the success of a large-scale
mplementation would depend on several untested assump-
ions, including the comparability of patients across low-
nd high-volume hospitals, the ability of hospitals to toler-
te large-volume increases and maintain their performance,
nd the “transferability” of volume effects across hospitals.
Increasing access to cardiovascular specialty care and
ore intensive treatments may have limited benefits. Poli-
ies that endorse universal access to primary PCI at regional
TEMI centers disregard reports of superior outcomes for
atients treated in collaborative care models using generalist
nd specialist physicians (23). Specialty care itself may lead
o more intensive treatment patterns that may not neces-
arily result in improved outcomes, but would drive up costs.
or instance, ACS patients treated in areas with higher rates
f invasive management have outcomes comparable to those
f patients treated in regions with lower rates of invasive
anagement but optimal medical care (24). Promoting the
pread of intensive, interventional management of ACS, as
ould likely occur in specialty-managed patients or at desig-
ated STEMI centers, belies the fact that many patients may
ot need nor even benefit from such treatment (25).
laim 3: European-based studies of transferring patients
or primary PCI are generalizable to the U.S. Evidence
upporting the benefits of transferring patients for primary
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Treatment of ST-Segment Elevation ACS April 4, 2006:1346–9CI is based on the results of five randomized controlled
rials conducted primarily in Europe (13,26–29). In addi-
ion to excluding patients who would not be suitable for
ransport, these studies were conducted in small geographic
egions with centralized hospital systems. In contrast, pop-
lations in the U.S. are more dispersed, emergency medical
ervices (EMS) more heterogeneous, and most hospitals are
ot directly government-administered. These differences lead
s to suggest caution in applying these results to the U.S.
Of greater concern is the lack of any direct data concern-
ng transferring patients for STEMI from populations in
he U.S. The only study of transfer to enroll patients in the
.S. was the Randomized Trial of Transfer for Primary
ngioplasty Versus On-site Thrombolysis in Patients with
igh-Risk Myocardial Infarction (Air-PAMI), and it en-
olled only 83 patients with STEMI over a three-year
eriod, or approximately one patient every four months, at
ts nine participating centers (28). This population repre-
ents 0.02% of the estimated 500,000 patients hospital-
zed for STEMI in the U.S. in any given year (30). It is clear
hat a more robust, generalizable evidence base is needed
efore implementing regionalization of STEMI care across
he entire U.S.
laim 4: STEMI regionalization can be organized like a
evel 1 trauma system. There are two major differences
etween trauma and STEMI care that undermine this
nalogy. First, the scale of STEMI care in terms of both the
umbers of patients affected and the resources needed is
uch larger than for trauma care. Regionalizing STEMI
are delivery would involve shifting resources on a massive
cale. Such a strategy would also require developing capac-
ties that are still experimental. Field-based electrocardio-
ram testing, a key component of the proposed system, has
roduced mixed results in limited studies and remains
ntested on a national scale (31,32). Moreover, unlike
rauma, ACS patients often present to the hospital directly,
ypassing EMS. In addition, even if such patients were to
se EMS, the diagnosis of STEMI or ACS is not always
lear: more than 80% of patients with symptoms suggestive
f ACS are not found to be experiencing acute cardiac
schemia, let alone STEMI (33). Given that there is a trend
or an increasingly smaller proportion of patients with ACS
o develop STEMI (34), regional ACS centers that directly
eceive symptomatic patients may find themselves swamped
y non-cardiac cases and patients with non–ST-segment
levation infarctions.
The difference in scale between ACS and trauma care
mplies that regionalizing STEMI care would be much
ore expensive and resource-intensive than it has been for
rauma. Not only would the up-front costs to reconfigure
TEMI care nationwide be exorbitant, but the ongoing
osts would be substantial as well. In particular, regional-
zation would impose a heavy burden on EMS providers,
ho would be responsible for transporting the large num-
ers of suspected STEMI patients for primary PCI. The
doption of STEMI regionalization and its associated iemands for transfer to STEMI centers would likely require
ither the expansion of current EMS capacity or reductions
n the availability of EMS for other needs.
Second, cardiovascular care, unlike trauma, is a financially
ttractive service for hospitals. For hospitals that provide
hem, cardiac procedures account for some 35% of total
ospital revenue on average (35), and that revenue is
requently needed to cross-subsidize other hospital services.
t is therefore not surprising that acute care general hospitals
ave sought to prevent the entry into their markets of
ardiac specialty hospitals, which, like regional ACS cen-
ers, threaten to take valued cardiac procedure volume and
ssociated revenues. Although both cardiovascular and
rauma services require substantial capital investments,
rauma services are not a notable source of hospital revenue.
A system of designated STEMI centers would reinforce
he division between the cardiac “haves” and the “have nots.”
t would be naive to think that hospitals not receiving a
egional STEMI center designation would willingly send
heir STEMI patients elsewhere. Policy makers should
xpect that the potential losers will resist regionalization
nder the current reimbursement system. Moreover, we are
ot optimistic that the adjustments to reimbursement envi-
ioned by Henry et al. (8) will be sufficient to address these
ospitals’ concerns. The threat of being left out under
egionalization may provide the necessary incentive for
ospitals to preemptively seek to satisfy criteria that may
arn them designation as regional STEMI centers, possibly
ncluding opening new cardiac catheterization labs or ex-
anding capacity in existing labs. In states without Certif-
cate of Need regulation, there is little to prevent this from
appening. A restrictive nationwide STEMI regionalization
olicy could collide with federal regulatory objectives, which
avor policies that promote, not inhibit, hospital competi-
ion. The U.S. Federal Trade Commission and the Depart-
ent of Justice recently recommended, for example, that
states should decrease barriers to entry into provider
arkets” (36). The assertion by Henry et al. (8) that
ufficient numbers of cardiologists will willingly staff non-
TEMI hospitals is similarly naive. This was made clear in
recent Connecticut Certificate of Need application in
hich a center petitioning for primary PCI services justified
ts request, in part, on its need to recruit and retain
ardiovascular specialists (37).
onclusions. Several issues merit consideration in the
iscussion of regionalized STEMI care. Current evidence
or the purported benefits of regionalizing STEMI care has
imitations, including limited applicability to the U.S.
ealth care system and no direct data that transferring
atients from low-volume PCI centers to high-volume PCI
enters reduces mortality. Hospital size, technology, and
pecialty care do not guarantee high-quality STEMI care,
ust as the absence of these factors does not preclude quality
are. Absent from discussion of the proposed policy are the
otential problems that may accompany regionalization,
ncluding feasibility, risks to patients, and the health care
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April 4, 2006:1346–9 Treatment of ST-Segment Elevation ACSystem. Although STEMI care regionalization has its pro-
onents, the current data are insufficient to endorse such a
undamental change in the health care system. Clear com-
elling evidence of the benefits of STEMI care regionaliza-
ion and a better understanding of its potential conse-
uences within the U.S. are needed before implementing
ny such national policy.
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